Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.525
-0.205 (-4.33%)
Sep 10, 2026, 1:02 PM EDT - Market open
Cytek Biosciences Revenue
Cytek Biosciences had revenue of $48.14M in the quarter ending June 30, 2026, with 5.57% growth. This brings the company's revenue in the last twelve months to $206.71M, up 5.44% year-over-year. In the year 2025, Cytek Biosciences had annual revenue of $201.49M with 0.52% growth.
Revenue (ttm)
$206.71M
Revenue Growth
+5.44%
P/S Ratio
2.85
Revenue / Employee
$303,092
Employees
682
Market Cap
588.17M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 201.49M | 1.04M | 0.52% |
| Dec 31, 2024 | 200.45M | 7.44M | 3.85% |
| Dec 31, 2023 | 193.02M | 28.98M | 17.67% |
| Dec 31, 2022 | 164.04M | 36.09M | 28.20% |
| Dec 31, 2021 | 127.95M | 35.11M | 37.82% |
| Dec 31, 2020 | 92.84M | 34.96M | 60.39% |
| Dec 31, 2019 | 57.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.36B |
| Varex Imaging | 865.00M |
| Tactile Systems Technology | 350.31M |
| OrthoPediatrics | 252.72M |
| Cerus | 221.55M |
| NeuroPace | 106.99M |
| Delcath Systems | 95.42M |
| Sight Sciences | 83.38M |
CTKB News
- 1 day ago - Sysmex Europe, Cytek Biosciences announce European collaboration - TheFly
- 1 day ago - Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry - GlobeNewsWire
- 6 days ago - Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS - GlobeNewsWire
- 8 days ago - Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding - GlobeNewsWire
- 4 weeks ago - Cytek Biosciences price target lowered to $5 from $5.50 at Morgan Stanley - TheFly
- 5 weeks ago - Cytek Biosciences reports Q2 EPS (9c), consensus (2c) - TheFly
- 5 weeks ago - Cytek Biosciences sees FY26 revenue $207M-$212M, consensus $208.83M - TheFly